NewEdge Advisors’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

NewEdge Advisors’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-333	Closed	-$222	–	3901
2023 Q3	$222	Hold	333	–	–	﹤0.01%	3316
2023 Q2	$1.1K	Hold	333	–	–	﹤0.01%	3228
2023 Q1	$3.03K	Hold	333	–	–	﹤0.01%	2929
2022 Q4	$4	Buy	+333	New	+$5.87K	﹤0.01%	3870
2021 Q3	–	Sell	-339	Closed	-$34K	–	1246
2021 Q2	$34K	Hold	339	–	–	﹤0.01%	1126
2021 Q1	$32K	Sell	339 -6	-2%	-$608	﹤0.01%	1022
2020 Q4	$28K	Hold	345	–	–	﹤0.01%	966
2020 Q3	$30K	Sell	345 -98	-22%	-$11.4K	﹤0.01%	907
2020 Q2	$41K	Buy	+443	New	+$24.4K	﹤0.01%	837
2020 Q1	–	Sell	-443	Closed	-$18K	–	916
2019 Q4	$18K	Hold	443	–	–	﹤0.01%	807
2019 Q3	$6K	Hold	443	–	–	﹤0.01%	814
2019 Q2	$16K	Buy	+443	New	+$24K	﹤0.01%	649

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NewEdge Advisors's VBIV Position: Q4 2023 in Review

NewEdge Advisors sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q4 2023, closing a stake of 333 shares — an estimated $222 sold.

NewEdge Advisors first reported a position in VBIV in Q2 2019 and held it in 12 quarters. The position peaked at $41K in Q2 2020. 39 funds tracked by Wall St. Rank hold VBIV as of Q4 2023.

NewEdge Advisors reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q4 2023 after selling out during the quarter.
NewEdge Advisors sold 333 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q4 2023, an estimated $222.
NewEdge Advisors first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2019 and held it in 12 quarters.
NewEdge Advisors's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $41K in Q2 2020.
39 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q4 2023.

Based on NewEdge Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.